ReviewFrontiers in immunology2021
Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Engineering immune cell engagers: From molecular constructs to biomaterial platforms.Materials today. Bio · 2026Review
- MYC promotes the progression of prostate cancer by regulating CD47 to induce an immunosuppressive microenvironment.Cellular and molecular life sciences : CMLS · 2026Article
- Optimizing antibody stability and efficacy in CD47- SIRPα inhibition via computational approaches.Molecular diversity · 2025Article
- Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments.Signal transduction and targeted therapy · 2025Review
- Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models.Molecular therapy. Nucleic acids · 2025Article
- Neutrophil extracellular traps impede cancer metastatic seeding via protease-activated receptor 2-mediated downregulation of phagocytic checkpoint CD24.Journal for immunotherapy of cancer · 2025Article
- Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment.Journal of pharmaceutical analysis · 2025Review
- Deciphering the role of CD47 in cancer immunotherapy.Journal of advanced research · 2024Review
- Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review).Oncology letters · 2024Review
- Pan-cancer analysis for the prognostic and immunological role of CD47: interact with TNFRSF9 inducing CD8 + T cell exhaustion.Discover oncology · 2024Article
- Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives.Frontiers in oncology · 2024Review
- Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy.Molecular therapy oncolytics · 2023Article
- Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery.Biosensors · 2023Article
- The role of CD47 in non-neoplastic diseases.Heliyon · 2023Review
- Targeting CD24 as a novel immunotherapy for solid cancers.Cell communication and signaling : CCS · 2023Review
- Review
- Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives.Acta pharmaceutica Sinica. B · 2023Review
- Emerging phagocytosis checkpoints in cancer immunotherapy.Signal transduction and targeted therapy · 2023Review
- The landscape overview of CD47-based immunotherapy for hematological malignancies.Biomarker research · 2023Review
- Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy.Oncology research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prosperity of immunological therapy for cancer has aroused enormous passion for exploiting the novel targets of cancer immunotherapy. After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia, a few of CD47-targeted bsAbs for cancer immunotherapy, are currently in clinical research. In our review of CD47-targeted bsAbs, we described the fundamental of bsAbs. Then, we summarized the information of four undergoing phase I researches, reviewed the main toxicities relevant to CD47-targeted bsAb immunological therapy of on-target cytotoxicity to healthy cells and a remarkable antigen-sink. Finally, we described possible mechanisms of resistance to CD47-targeted bsAb therapy. More clinical researches are supposed to adequately confirm its security and efficacy in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.